Get started
Author

Manuel Constenla

Observed names: M Constenla, M. Constenla, Manuel Constenla -
Observed institutions: St George's Hospital, The University of Texas MD Anderson Cancer Center, Merck KGaA, Darmstadt (Germany), Hospital de Sant Pau, Unidade Local de Saúde de Coimbra, Taipei Veterans General Hospital, Hospital General Universitario Gregorio Marañón, AC Camargo Hospital, Russian Cancer Research Center NN Blokhin, Althaia, Centro Oncológico de Galicia, Institut Català d'Oncologia, Hospital Virgen de la Salud, Hospital Universitario Miguel Servet, Institute of Oncology NN Petrov, Hospital Clínico de la Universidad de Chile, Grupo Gallego de Cáncer de Pulmón, Fundación Arturo López Pérez, Duran i Reynals Hospital, Hôpitaux Universitaires de Strasbourg, Hospital Universitari Germans Trias i Pujol, Complejo Hospitalario Universitario de Albacete, Complejo Hospitalario de Pontevedra, Hospital Montecelo, GEICAM – Spanish Breast Cancer Group, Hospital Universitario Sanitas La Moraleja, Sanitas (Spain), University of Chile
ORCID: 0000-0001-5864-5184
Observed ORCID: 0000-0001-5864-5184
OpenAlex ID: A5033260833
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 · Eric Van Cutsem, Vladimir M. Moiseyenko, et al. · Journal of Clinical Oncology · 1,946
PDF
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
2007 · R. Rosell, G. Robinet, et al. · Annals of Oncology · 262
PDF
Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group
2007 · Jaffer A. Ajani, Vladimir M. Moiseyenko, et al. · Journal of Clinical Oncology · 249
Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group
2007 · Jaffer A. Ajani, Vladimir M. Moiseyenko, et al. · Journal of Clinical Oncology · 184
A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy
2005 · X. León, R. Hitt, et al. · Clinical Oncology · 181
Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)
2004 · R. Rosell, C. Daniel, et al. · Journal of Clinical Oncology · 142
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study
2008 · Ruth Pettengell, Matthias Schwenkglenks, et al. · Supportive Care in Cancer · 137
PDF
Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia Study
2008 · Ruth Pettengell, André Bosly, et al. · British Journal of Haematology · 103
PDF
Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)
2005 · V. M. Moiseyenko, J. Ajani, et al. · Journal of Clinical Oncology · 73
Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study
2010 · Matthias Schwenkglenks, Ruth Pettengell, et al. · Supportive Care in Cancer · 68
PDF
Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment
2006 · Matthias Schwenkglenks, Christian Jackisch, et al. · Supportive Care in Cancer · 64
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
2004 · N Batista, G Perez-Manga, et al. · British Journal of Cancer · 48
PDF
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study
2002 · Manuel Constenla, Ramon Garcia-Arroyo, et al. · Gastric Cancer · 42
PDF
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
2007 · G. Romieu, M. Clemens, et al. · Critical Reviews in Oncology/Hematology · 36
Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma
2000 · J. Feliu, M. P. L�pez �lvarez, et al. · Cancer · 32
PDF
5-HT 3 Receptor Antagonists for Prevention of Late Acute-Onset Emesis
2004 · Manuel Constenla · Annals of Pharmacotherapy · 30
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS
2018 · E. Arriola, A. Paredes-Lario, et al. · Clinical & Translational Oncology · 27
PDF
Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis
2015 · Miguel Martín, Noelia Martínez, et al. · The Oncologist · 27
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
2008 · E. Aranda, M. Valladares, et al. · Annals of Oncology · 23
Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer
2010 · José-María Roca, Vicente Alonso, et al. · Chemotherapy · 22
Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention
2017 · J. F. Cueva, S. Antolín, et al. · Clinical & Translational Oncology · 18
PDF
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study
2005 · A. Font, A. Murias, et al. · Annals of Oncology · 18
Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts
2019 · Carlos Camps, Antonio Antón Torres, et al. · Journal of Pain Research · 14
PDF
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor‐positive metastatic breast cancer: A confirmatory prospective study
2007 · Ramon Colomer, Antonio Llombart‐Cussac, et al. · Cancer · 14
PDF
Dose-limiting effects of neutropenic events in six European audits of adjuvant breast cancer chemotherapy
2004 · T. D. Szucs, R. Leonard, et al. · Journal of Clinical Oncology · 14
Works count: 89
Citation count: 3,942
H-index: 20
I10-index: 32
Year
Topic
Type